ALIPAY
25.8.2021 11:27:08 CEST | Business Wire | Press release
Ant Forest, a tree-planting mini program in the Alipay app that enables users to earn virtual points for making low-carbon lifestyle choices, today announced that it has helped over 600 million users plant more than 326 million trees since it launched in 2016, contributing to reforestation efforts in some of China’s most arid regions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210825005340/en/
“Going green has always been part of our calling, but we know that one company’s effort is far from enough. That is why we need to create an innovative open platform, where individuals, NGOs, and brands can work together to protect the environment through low-carbon lifestyle choices”, said Yijie Peng, President of Social Good and Green Development at Ant Group. “We are excited that over 100 brands have chosen to work with Ant Forest in offering low-carbon lifestyle incentives to users, and we look forward to working with even more partners in the future.”
When users make environmentally friendly lifestyle choices, such as paying utility bills online instead of asking for paper invoices, or taking public transportation to work instead of driving, the choices are counted and converted into virtual “green energy points” that accumulate to grow virtual “trees” in the Ant Forest mini program on Alipay.
After accumulating enough points, users can convert their virtual trees into real ones, which are then planted by Alipay and its philanthropic partners in areas that need reforesting. Ant Forest users can also donate their green energy points to help preserve wildlife diversity. To better protect biodiversity, Ant Forest has partnered with various environmental NGOs to provide shelter for over 1,500 species in 18 protected areas across 10 provinces in China.
Many businesses, including international brands like Starbucks, Timberland and Estée Lauder, have also set up their own virtual forests within the Alipay app, where fans of the brands can join their efforts to protect the environment. These fans can opt to donate a certain amount of their own green energy points to branded virtual forests, which are later converted into real trees planted in areas that need to be reforested. As of August 2021, users had donated green energy points to Estée Lauder, Timberland, and Starbucks’ branded virtual forests more than one billion times in total.
Currently, more than 100 brands including chain restaurants, home appliance makers and food delivery companies work with Ant Forest so that when customers make low-carbon lifestyle choices, such as choosing not to ask for disposable cutlery when ordering food or purchasing home appliances with high energy efficiency, they can earn green points. Users can then donate these points to plant trees or to support biodiversity in protected areas.
In 2019, Alipay Ant Forest was awarded the “UN Champions of the Earth” award – the United Nation’s highest environmental honor – for leveraging digital technology to inspire hundreds of millions of people to take greener actions in their daily lives. In the same year, Alipay Ant Forest also won the 2019 UN Global Climate Action Award for using digital technologies to scale up climate action.
About Alipay
Alipay is the leading digital payment platform in China, serving hundreds of millions of users, and connecting them with merchants and partner financial institutions that offer inclusive financial services and digital daily life services such as food delivery, transport, entertainment, and healthcare.
Ant Group, the owner and operator of Alipay, has further introduced the global cross-border mobile payments and marketing solution Alipay+, which enables merchants, especially small and medium-sized businesses, to better serve consumers from all over the world by collaborating with global partners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210825005340/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom